NEW YORK, March 10, 2016 /PRNewswire/ -- How well does your Asthma/COPD medical affairs team compare with your rivals in the US?
Which brand's medical affairs team is perceived to be the best and which is the worst? Who scored almost 5 times better on the quality of overall interactions than the worst performers?
Find out how well your medical affairs team ranks and where physicians are still looking for improvements – specifically from your team and more generally. Get the report now.
Don't forget, if you also buy the EU5 version you'll get a free comparison report, saving you time understanding and analysing the differences uncovered between these crucial markets.
Packed with physician insight into seven of the leading asthma/COPD brands:
AstraZeneca? Symbicort (Budesonide/Formoterol)? Tudorza (Aclidinium)
Boehringer Ingelheim? Spiriva (Tiotropium)
Forest Laboratories? Daliresp (Roflumilast)
Genentech / Novartis? Xolair (Omalizumab)
GlaxoSmithKline? Advair (Fluticasone/Salmeterol)? Anoro Ellipta (Umeclidinium/Vilanterol)
Novartis? Arcapta (Indacaterol)
Reputations vary considerably: There is a wide spread in how the individual teams are perceived in the important categories with some teams consistently highly rated
Physicians think there's a solid performance: Areas of high importance score best overall
Important areas scored higher: Medical affairs teams score more room for improvement in areas of lower importance
Information needs score highest: Highest satisfaction is achieved around fulfilling information requirements
US outperforming EU5: Physicians rate US medical affairs teams higher – with more scores for solid performance
1 brand lags behind: Who scored lowest on all important attributes?
Key issues explored
The reputations of the medical affairs teams specialising in asthma/COPD evaluated using proprietary analysis and visualisation tools to show how the teams are perceived
How medical affairs teams are being used by physicians and where they are seeking support
How often physicians want contact with medical affairs teams
What services from medical affairs teams are considered the most and least important
Analysis of performance and where improvement is still needed across key categories, both overall and on a drug-by-drug basis
A mix total of 100 pulmonologists (67) and general practitioners (33) across the US participated in this study
Data was collected via a 15-minute internet-based questionnaire
Participants screened to ensure they:
See at least 50 patients for asthma or COPD in a typical month
Have been in active practice between 3-35 years
Devote at least 50% of their time to direct patient care
Have interacted with a medical affairs professional in the past 6 months for at least 1 of the listed products
Read the full report: http://www.reportlinker.com/p03607559-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001